In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $130.00. The company’s shares closed yesterday at $106.98.
Goldstein covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Merck & Company, and Nektar Therapeutics. According to TipRanks, Goldstein has an average return of -2.8% and a 33.40% success rate on recommended stocks.
In addition to Mizuho Securities, Merck & Company also received a Buy from Berenberg Bank’s Luisa Hector in a report issued on January 31. However, on the same day, UBS maintained a Hold rating on Merck & Company (NYSE: MRK).
See the top stocks recommended by analysts >>
Based on Merck & Company’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $14.96 billion and a net profit of $3.25 billion. In comparison, last year the company earned a revenue of $13.15 billion and had a net profit of $4.57 billion
Based on the recent corporate insider activity of 62 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MRK in relation to earlier this year. Most recently, in November 2022, Robert M. Davis, the CEO & President of MRK sold 167,613.00 shares for a total of $17,168,949.76.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
Read More on MRK:
- Merck’s Keytruda approved by FDA for non-small cell lung cancer treatment
- Another Feather on Merck’s Cap: Keytruda’s NSCLC Treatment Gets Another Indication
- Merck Animal Health announces FDA approval for Bravecto Chews for Dogs
- Merck to stop Phase 3 KEYNOTE-991 trial
- Merck reports ‘positive’ results from Phase 3 KEYNOTE-966 trial